27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks advanced in the holiday-shortened week, with upside driven mainly by the broader market strength. Reflecting the extreme volatility in the space, a few stocks gyrated wildly in reaction to catalytic events.
ChemoCentryx Inc (NASDAQ:CCXI) nearly tripled in a single session in reaction to positive Phase 3 data for drug to treat rare inflammatory disease.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Medicines Company (NASDAQ:MDCO) was another standout gainer, adding about 22% Monday, on a deal to be bought by Novartis AG (NYSE:NVS).
Here are the key catalysts for the unfolding week.
Conferences
- International Alliance of Amyotrophic Lateral Sclerosis/Motor Neurone Disease, or ALS/MND, Annual Meeting – Dec. 1-2 in Perth, Australia
- 34th World Cardiology Conference – Dec. 2-3 in Barcelona, Spain
- Annual Congress on Antibiotics and Antimicrobial Resistance - Dec. 2-3 in Paris, France
- 6th Annual Conference on Stroke and Neurological Disorders - Dec. 2-3 in Rome, Italy
- 10th International Conference on Immunology & Immunogenetics - Dec. 2-3 in London
- 12th Clinical Trials On Alzheimer's Disease, or CTAD – Dec. 4-7 in San Diego, California
- Piper Jaffray 31st Annual Healthcare Conference – Dec. 3-5 in New York City
- Evercore ISI HealthCONx Conference – Dec. 3-5 in Boston, Massachusetts
- 2nd Global Conference on Cardiovascular Research and Clinical Cardiology – Dec. 6-7 in Montreal, Canada
- American Epilepsy Society, or AES, 2019 Annual Meeting – Dec. 6-10 in Baltimore, Maryland
- 61st American Society of Hematology, or ASH, Annual Meeting – Dec. 7-10 in Orlando, Florida
PDUFA Dates
The FDA is scheduled to give its verdict on Roche Holdings AG Basel ADR's (OTC:RHHBY) Tecentriq in combination with Bristol-Myers Squibb Co's (NYSE:BMY) chemo medications Carboplatin and Abraxane in patients with metastatic non-squamous NSCLC, who do not have EGFR or ALK genomic tumor aberrations. The PDUFA action date is fixed for Monday.
Clinical Readouts
CTAD Presentations
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – detailed Phase 3 data for pimavanserin in dementia-related psychosis (Wednesday)
Biogen Inc (NASDAQ:BIIB) – Detailed data from the Phase 3 EMERGE study of aducanumab in Alzheimer's disease (Thursday)
Cassava Sciences Inc (NASDAQ:SAVA) – Phase 2a data for PTI-125 in Alzheimer's disease (Thursday)
Alector Inc (NASDAQ:ALEC) – Phase 1 data for AL002, a monoclonal antibody, in Alzheimer's disease (Friday)
International Alliance of ALS/MND Annual Meeting Presentations
Cytokinetics, Inc. (NASDAQ:CYTK) – Responder and subgroup analyses of data from the Phase 2 study of Reldesemtiv in ALS (Thursday)
See Also: A Deep Dive Into Aquestive Following The FDA's Approval Of Riluzole
AES Annual Meeting Presentations
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) – Phase 3 data for Epidiolex in tuberous sclerosis leukemia (Saturday)
ASH Presentations
(Scheduled for Saturday)
Magenta Therapeutics Inc (NASDAQ:MGTA) – initial Phase 1 data for MGTA-145 in healthy volunteers
Bristol-Myers Squibb – Phase 1 data for liso-cel, or JCAR017, in relapsed/refractory B cell non-Hodgkin lymphoma
Fortress Biotech (NASDAQ:FBIO) and Mustang Bio Inc (NASDAQ:MBIO) – Phase 1/2 data for MB-107 in X-linked severe combined immunodeficiency
Sierra Oncology Inc (NASDAQ: SRRA – Phase 3 data for momelotinib in myelofibrosis
Actinium Pharmaceuticals Inc (NYSE:ATNM) – Phase 3 data for lomab-B in acute myeloid luekemia
bluebird bio Inc (NASDAQ:BLUE) – Phase 1/2 data for LentiGlobin in sickle cell disease
Morphosys Ag (NASDAQ:MOR) – Phase 2 data for MOR208 and Gilead Sciences, Inc. (NASDAQ:GILD)'s Zydelig in chronic lymphocytic leukemia Unum Therapeutics Inc (NASDAQ:UMRX) – Phase 1 data for ACTR707 with Roche's Rituxan in CD20 positive non-Hodgkin lymphoma and Phase 1 data for ACTR087 plus Rituxan, also in non-Hodgkin lymphoma
Verastem Inc (NASDAQ:VSTM) – Phase 2 data for duvelisib in peripheral T-cell lymphoma
Autolus Therapeutics Ltd – ADR (NASDAQ:AUTL) – interim Phase 1 data for AUTO3 in relapsed/refractory diffuse large B-cell lymphoma and updated Phase 1 data for AUT01 in acute lymphoblastic leukemia
TrovaGene Inc (NASDAQ:TROV) – Phase 1/2 data for ovansertib in acute myeloid leukemia
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) – initial Phase 1 data for CYC065 plus AbbVie Inc (NYSE:ABBV)'s venetoclax in chronic lymphocytic leukemia
Oncternal Therapeutics Inc (NASDAQ:ONCT) – Phase 1/2 data for cirmtuzumab plus AbbVie's ibrutinib in chronic lymphocytic leukemia and mantle cell lymphona
Sangamo Therapeutics Inc (NASDAQ:SGMO) – Phase 1/2 data for SB-525 in hemophilia A
Acceleron Pharma Inc (NASDAQ:XLRN) and Bristol-Myers Squibb – Phase 2 data for luspatercept in hemophilia A
IPO Quiet Period Expirations
Centogene N.V./EQ (NASDAQ:CNTG)
Galera Therapeutics Inc (NASDAQ:GRTX)
TELA Bio Inc (NASDAQ:TELA)
CNS Pharmaceuticals Inc (NASDAQ:CNSP)
89bio Inc (NASDAQ:ETNB)
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.